AstraZeneca Amends its Development and Commercialization Agreement with Ironwood for Linzess (linaclotide) Signed in 2012 

AstraZeneca Amends its Development and Commercialization Agreement with Ironwood for Linzess (linaclotide) Signed in 2012

Shots:

  • Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024, ~$90M as a milestone with royalties on sales of Linzess in China mainland, China Hong Kong and China Macau. AstraZeneca to get full rights to develop, manufacture & commercialize Linzess in China
  • In Oct’2012, the companies collaborated to co-develop and co-commercialize Linzess and were jointly responsible for strategic oversight of the development and commercialization of Linzess in China while AstraZeneca had primary responsibility for local operational execution
  • Linzess is a guanylate cyclase-C (GC-C) agonist, binds to it leading to an increased intestinal fluid secretion and accelerated transit with a decrease in the activity of pain-sensing nerves in the intestine and has received NMPA’s approval for irritable bowel syndrome with constipation (IBS-C) in Jan’2019 with its expected launch in 2019

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: The Star